Study of RYZ101 in Combination With SoC in Subjects With SSTR+ ES-SCLC

Exclusion Criteria

• •Prior exposure to immune-mediated therapy,
• •Known active or suspected autoimmune disease or any condition requiring systemic treatment with immunosuppressive medications within 14 days prior to first dose of study drug
• •History of idiopathic pulmonary fibrosis, organizing pneumonia (e.g., bronchiolitis obliterans), drug-induced pneumonitis, or idiopathic pneumonitis. Note: History of radiation pneumonitis is permitted.
• •Severe infection within 4 weeks and/or treatment with therapeutic oral or i.v. antibiotics within 2 weeks prior to initiation of study treatment.
• •Prior allogeneic stem cell or solid organ transplantation.
• •Treatment with a live, attenuated vaccine within 4 weeks prior to initiation of study treatment, or anticipation of need for such a vaccine during atezolizumab treatment or within 5 months after the final dose of atezolizumab.
• •Radiotherapy to the chest prior to systemic therapy or planned consolidation chest radiation therapy. Radiation therapy outside of the chest for palliative care is allowed but must be completed \>2 weeks prior to first dose of study drug.
• •Significant cardiovascular disease and/or resistant hypertension
• •Subjects with previously treated central nervous system (CNS) metastases who have not recovered from acute side effects of radiotherapy.